Download Stanford Profiles: /viewResume

CURRICULUM VITAE
Edda Frauke Spiekerkoetter, MD
Address:
Division of Pulmonary and Critical Care Medicine
Department of Medicine
Stanford University Medical Center
300 Pasteur Drive, Rm H3134
Stanford, CA 94305-5162
E-mail: [email protected]
Phone: (650) 723-6381
Fax: (650) 723-6700
Cell: (650) 739-5031
1. Education/Training:
Dec 1995
MD Thesis: Magna cum laude
Passive smoking exposure in school aged children in
Southwest Germany University of Freiburg, Department of
pediatrics. Germany. Mentor: Prof J Forster.
April 1991 - Dec 1995
Sept 1988 - Mar 1991
Sept 1986 - Sept 1988
Medicine, Albert-Ludwigs-University Medical School, Freiburg,
Germany
Degree: MD
Medicine, Eberhardt-Karls University of Tuebingen, Germany
Biology, Eberhardt-Karls University of Tuebingen, Germany,
Degree: Bachelor of Science
2. Licensure and Certification:
Sept 2009
Full Privileges in Pulmonary and Critical Care Medicine,
Stanford University Medical Center
Aug 2009
Medical License, Medical Board of California, Expiration
7/31/2013
Sept 2006
Educational Commission for Foreign Medical Graduates
(ECFMG) certification
USMLE Step1 July 2006, USMLE Step 2 CK Aug 2006,
USMLE 2 CS Sept 2006, USMLE Step 3 Jul 2007
Aug 2002
Board Certification Internal Medicine, Germany
Page 1
Edda Spiekerkoetter, MD
3. Positions and Employment
Professional activity:
June 2012 – current
Assistant Professor of Medicine, Division of Pulmonary and
Critical Care Medicine, Stanford University
Dec 2011 – June 2012
Acting Assistant Professor of Medicine, Stanford University
Sept 2009 – Nov 2011
Instructor of Medicine and staff attending physician, Division of
Pulmonary and Critical Care, Adult Pulmonary Hypertension
Service, Stanford University
Sept 2009 - August 2011 K12 Scholar ”Stanford career development program in
Genetics and Genomics of pulmonary diseases”.
Director: Dr. Mark Krasnow
Mentors: Dres. Marlene Rabinovitch and Phil Beachy
Project: Modulating BMPRII signaling in Pulmonary Arterial
Hypertension
July 2008 - June 2009
Critical Care Fellow, Stanford University Hospital and Clinics,
Stanford
July 2007 - June 2008
Pulmonary and Critical Care Fellow, Stanford University
Hospital and Clinics, Stanford
Feb 2007 - May 2007
Pulmonary Hypertension Database management, Stanford
University
Oct 2002 - Jan 2007
Postdoctoral research fellow, Department: Pediatric Cardiology,
Prof. Dr. M. Rabinovitch, Stanford University Medical School,
Stanford
March 1996 - Sept 2002 Residency: Internal Medicine and
Fellowship: Pulmonary and Critical Care at
Medical School Hannover, Department of Respiratory and
Critical Care Medicine. Director: Prof. Dr. med. H. Fabel
Including: 1 year: Lung transplant fellow
1/2 year: Pulmonary Hypertension fellow (outpatients, rightheart catheterization, clinical trials of new therapeutic drugs for
pulmonary hypertension)
Teaching:
Stanford University/Stanford Medical Center:
Sept 2010 - present
Organization of a 2-weekly Clinical Topics Series in Pulmonary
Hypertension
Sept /2012 - present
Organizer of bi-weekly Basic Science Journal Club on
Pulmonary and Cardiovascular Topics
Page 2
Edda Spiekerkoetter, MD
2006 - present
2005 - present
2005-2006
Lecturer in Cardiovascular and Pulmonary Science Seminar
(Med 223, Cardiovascular Pulmonary Research Scholarly
Concentration for Medical Students)
Supervision of laboratory projects of undergraduates and
summer students
Katie Lynn Pricola – Medical Student
Topic: SDF-1 and Pulmonary Hypertension
2006
Alexandra Bruneau - Visiting Researcher, France
Topic: Measurement of elastase activity in mice after murine HV-68
infection
2010
Leila Haghighat – undergraduate UCSD
Topic: MiR21 expression in PAECs from patients with pulmonary
hypertension and healthy controls
2010
Roxanna Haghighat – summer student
Topic: Id-1 expression and Smad signalling in PAECs from patients
with pulmonary hypertension and healthy controls
2011
Roshelle Chan – undergraduate SFSU
Topic: Role of FK-506 on pulmonary artery smooth muscle cells
2013
Jerry Kuang – undergraduate Stanford
Topic: BMP signaling and Endothelial Mesenchymal Transition
July 2007 - June 2009
Since 2012
Lectures on ICU related topics for residents, interns and
medical student
Lecture in Lung Lab I and Pulmonary Examination for First
Year Medical students
Medical School Hannover:
March 1996 - Sept 1997 Internal Medicine (School of Nursing)
March 1996 - Sept 2002 Medical Students: Practice of examination and history taking
Jan 2000 - Sept 2002
Lectures: Pathophysiology of the lungs; Practical Pneumology
Supervision of medical students working on their doctoral thesis
in the field of respiratory medicine, pulmonary hypertension
Technical Experience:
Surgical techniques:
Closed chest vascular and heart catheterization (in mice, rats)
Heart-Lung Preparation: performed in mice and rats.
Hemodynamic measurements: Right ventricular systolic pressure and mean arterial
pressure measurements, cardiac functions measurements performed in mice and
rats.
Implantation of subcutaneous infusion pumps in mice and rats
Endotracheal instillation of medication in mice
Page 3
Edda Spiekerkoetter, MD
Molecular Biology: PCR, quantitative RT-PCR, genomic DNA isolation, RNA
purification, Western blotting, Southern blotting, Liposomal and retroviral transfection
of primary cells, siRNA, miRNA mimics and antagomirs, DNA microarray
Cell Culture: Culture of human pulmonary artery smooth muscle and endothelial
cells. Organ culture of human and mouse lung.
Cell Biology Assays: Migration assays using Boyden chambers, PCNA , TUNEL and
Proliferation assays.
Microscopy: Bright Field, Fluorescence, and Confocal microscopy.
Histology: Paraffin embedding and hemotoxylin/eosin and Hart’s staining.
Immunohistochemistry and immunofluorescence. Assessment of morphological
parameters in pulmonary arteries, lungs, and hearts of mice.
Micro CT: Scanning and reconstructing of barium infused lungs in mice.
Biochemical assays: Elastase activity Assay
Development of a High Throughput Screen of FDA approved drugs and Small
molecules to test for compounds that activate or inhibit BMPRII signaling using as
luciferase reporter system.
4. Awards:
Feb 2014
Jan 2014
Sept 2012
Sept 2011- Aug 2016
Manuscript Award of the Cardiovascular Institute at Stanford
Poster Award: Joint Symposium Excellence Cluster CardioPulmonary System (ECCPS) and Pulmonary Vascular
Research Institute (PVRI) Giessen, Bad Naunheim, Germany
January 2014. Session: Molecular Mechanisms and Treatment
of Heart and Lung Disease“ Increasing BMPR2 signaling with
FK506 prevents endothelial mesenchymal transition in coronary
artery endothelial cells”
Winner of Poster competition Cardiovascular Institute Stanford
Supplemental award of the Pulmonary Hypertension
Association (PAH)
Sept 2011 - Aug 2016
K08 Career development award - NIH
Sept 2009 - Aug 2011
Career Development Award - K12 – NIH5K12HL089989
March 2003 - Feb 2005
Postdoctoral Research Fellowship of the Pulmonary
Hypertension Association (PHA) and American Heart
Page 4
Edda Spiekerkoetter, MD
5. Other Experience and Professional Memberships:
Member ATS (1997 – present)
Member AHA (2004- present)
Fellow Pulmonary Vascular Research Institute (2009 – present)
Faculty, Vera Moulton Wall Center For Pulmonary Vascular Disease (2009- present)
Member, Stanford Cardiovascular Institute (2009- present)
Reviewer
Journal of Clinical Investigation
European Respiratory Journal
European Journal of Clinical Investigation
American Journal of Respiratory Cell and Molecular Biology
PLoS ONE
Cobre Pilot Grant program of the University of Kansas Medical Center
Organizing committee and speaker at the Wall Center Symposium entitled “BMPR2 in
Pulmonary Hypertension”, Stanford University, September 10th 2012
Session Chair of Mini-Symposium D97 - PULMONARY HYPERTENSION: NEW
INSIGHTS INTO CAUSES AND TREATMENTS?
ATS 2012, Wed May 23 2012
Pulmonary Circulation Program Committee for the 2014 American Thoracic Society
International Conference
Phase II clinical Trial: TRANSFORM
Low dose FK506 for the treatment of Pulmonary Arterial Hypertension
Role: PI , in collaboration with Roham Zamanian
First Patient enrolled: Sept 2012, Currently 23/40 patients enrolled
Patent application filed by OTL at Stanford University
Use of FK506 for the treatment of Pulmonary Arterial Hypertension
Provisional patent: May 2, 2011 as U.S Provisional Application Serial No 61/481317
Patient application: May 2, 2012 EFS ID: 9993541 Application Number: 61481317
Since 2012 Abstract Reviewer for
American Heart Association Conference
Session 508. Pulmonary Circulation, Respiratory Processes, and Lung Injury
Since 2013 Abstract Reviewer for American Thoracic Society Conference
6. Languages:
fluency: English, German
basic knowledge: French, Latin
7. Publications:
Peer-Reviewed Publications:
Page 5
Edda Spiekerkoetter, MD
Sawada H, Saito T, Nickel NP, Alastalo TP, Glotzbach JP, Chan R, Haghighat L, Fuchs G,
Januszyk M, Cao A, Lai YJ, Perez VD, Kim YM, Wang L, Chen PI, Spiekerkoetter E,
Mitani Y, Gurtner GC, Sarnow P, Rabinovitch M. Reduced BMPR2 expression induces
GM-CSF translation and macrophage recruitment in human and mice to exacerbate
pulmonary hypertension. J Exp Med. 2014 Jan 20
Brunner NW, Ramachandran K, Kudelko KT, Sung YK, Spiekerkoetter E, Yang PC,
Zamanian RT, Perez Vde J. A case of recurrent pericardial constriction presenting with
severe pulmonary hypertension. Pulm Circ. 2013 Apr;3(2):436-9.
Spiekerkoetter E, Tian X, Cai J, Hopper K, Sudheendra D, Li CG, El-Bizri N, Sawada H,
Haghighat R, Chan R, Haghighat L, De Jesus Perez V, Wang L, Reddy S, Zhao M,
Barnstein D, Solow-Cordero, DE, Beachy PA, Wandless TJ, ten Dijke P Rabinovitch M
FK506 activates BMPR2 Signaling, rescues endothelial dysfunction, reverses pulmonary
hypertension . J Clin Invest, J Clin Invest. 2013 Aug 1;123(8):3600-13
de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge
RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian R. Safety and efficacy of
transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial
hypertension. Am J Cardiol. 2012 Nov 15;110(10):1546-50.
de Jesus Perez VA, Yuan K, Orcholski ME, Sawada H, Zhao M, Li CG, Tojais NF, Nickel
NP, Rajagopalan V, Spiekerkoetter E, Wang L, Dutta R, Bernstein D, Rabinovitch M.
Loss of Adenomatous Poliposis Coli-α3 Integrin Interaction Promotes Endothelial
Apoptosis in Mice and Humans. Circ. Res 2012 Sept 25 [Epub ahead of print]
Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S,
Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M. Neutrophil Elastase Is Produced by
Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions. Am J Pathol.
2011 Jul 14. [Epub ahead of print]
Perez VA, Ali Z, Alastalo TP, Ikeno F, Sawada H, Lai YJ, Kleisli T, Spiekerkoetter E, Qu
X, Rubinos LH, Ashley E, Amieva M, Dedhar S, Rabinovitch M. BMP promotes motility and
represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell
Biol. 2011 Jan 10;192(1): 171-88
Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo T-P, Powers JM, Wang L,
Lawrie A, Ambartsumian A, Schmidt AM, Berryman M, Ashley RH, Rabinovitch M. S100A4
and BMP-2 Co-Dependently Induce Vascular Smooth Muscle Cell Migration via pERK and
Chloride Intracellular Channel 4 (CLIC4). Circ Res. 2009 Sep 25;105(7): 639-47
Spiekerkoetter E, Alvira CM, Kim Y-M, Bruneau A, Pricola KL, Wang L, Ambartsumian N,
Rabinovitch M. Reactivation of gHV68 Induces Neointimal Lesions in Pulmonary Arteries
of S100A4/Mts1 Over-expressing Mice in Association with Degradation of Elastin. Am J
Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L276-89.
Page 6
Edda Spiekerkoetter, MD
Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T,
Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007 Dec;30(6):1096-102.
Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal- oriented
Treatment and Combination therapy for Pulmonary Arterial Hypertension. Eur Resp J 2005
Nov;26(5):858-63.
Spiekerkoetter E, Lawrie A, Merklinger S, Ambartsumian N, Lukanidin E, Schmidt AM,
Rabinovitch M. Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell
migration through multiple signaling pathways. Chest. 2005 Dec; 128 (6 Suppl):577S.
Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K,
Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M,
Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased Fibulin-5 and Elastin in
S100A4/Mts1 Mice with Pulmonary Hypertension. Circ Res. 2005 Sep 16;97(6):596-604.
Epub 2005 Aug 18.
Lawrie A, Spiekerkoetter E, Martinez E, Ambartsumian N, Sheward WJ, MacLean MR,
Hramar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent Serotonin
Transporter and Receptor pathways regulate S100A4/Mts1, a gene associated with cancer
and vascular disease. Circ Res. 2005 Aug 5;97(3):227-35.
MM Hoeper, Taha N, Bekjarova R, Gatzke R, Spiekerkoetter E. Bosentan treatment in
patients with primary pulmonary hypertension receiving nonparental prostanoids. Eur
Respir J 2003;22:330-334.
Spiekerkoetter Edda, Helmut Fabel, Marius M. Hoeper. Effects of inhaled sabutamol in
primary pulmonary hypertension. Eur Resp J. 2002 Sept;20(3):524-8
Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost
for treatment failure of aerolized iloprost in pulmonary arterial hypertension. Eur Respir J.
2002 Aug;20(2):339-43.
Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E,
Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary
hypertension with inhaled iloprost. Pneumologie, 2001 Jan; 55(1):38-43.
Hoeper MM, Spiekerkoetter E, Fabel H. Aerolized iloprost for Primary Pulmonary
Hypertension. Letter to the editor. N.Engl J. Med. 2000 Nov 9; 343 (19): 1421-1422.
Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E,
Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary
hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med. 2000 Jun 22;
342(25): 1866-77.
Page 7
Edda Spiekerkoetter, MD
Hoffmeyer F, Hoeper MM, Spiekerkotter E, Harringer W, Haverich A, Fabel H,
Niedermeyer J. Azathioprine withdrawal in stable lung and heart/lung recipients receiving
cyclosporine-based immunosuppression. Transplantation. 2000 Aug 15; 70(3): 522-5.
Spiekerkoetter E, Krug N, Hoeper M, Wiebe K, Hamm M, Harringer W, Haverich A, Fabel
H. Prevalence of malignancies after lung transplantation. Tranplant Proc. 1998 Jun;
30(4):1523-4.
Henschen M, Frischer T, Pracht T, Spiekerkotter E, Karmaus W, Meinert R, Lehnert W,
Werle E, Kuehr J. The internal dose of passive smoking at home depends on the size of
the dwelling. Environ Res. 1997 Jan; 72(1): 65-71.
Peer Reviewed Publications - Pending
In preparation:
Spiekerkoetter E, Hsi A, Fortenko O, Saito S, Kudelko K, Hsi A, de Jesus Perez VA,
Zamanian R. Vasoresponsiveness combined with capacitance is a prognostic indicator in
Pulmonary Arterial Hypertension
Edda Spiekerkoetter, Yon Sung, Deepti Sudheendra, Matthew Bill, Micheala A Aldred,
Mariëlle C. van de Veerdonk, Anton Vonk Noordegraaf, Janel Long-Boyle, Rajesh Dash,
Phil Yang, Marlene Rabinovitch and Roham T Zamanian. Low dose FK-506 in End-Stage
Pulmonary Arterial Hypertension
Reviews:
E. Spiekerkoetter, J Niedermeyer, MM Hoeper. Die pulmonale arterielle Hypertonie.
Internist. Praxis 2004; 44:1-14.
E. Spiekerkoetter, M Hoeper. New Therapies in pulmonary arterial hypertension. Estratto
da Minerva Pneumologica 2002;41 (4):127-136.
Spiekerkoetter Edda, Helmut Fabel, Marius M. Hoeper. Behandlung der schweren
pulmonalen Hypertonie. Deutsches Ärzteblatt, 2001 Aug; 98(33): 1697-1701.
Book Chapters:
Cissarek et al: Gefaessmedizin: Therapie und Praxis. Spiekerkoetter Edda Kapitel: Die
akute Lungenembolie und pulmonale arterielle Hypertonie. ABW Wissenschaftsverlag,
Berlin. 2009
Cissarek et al: Vascular Medicine: Therapy And Practice. Spiekerkoetter Edda: Chapter:
Acute pulmonary embolism and pulmonary Arterial Hypertension. Mcgraw-hill Professional
Publishing 2010.
Page 8
Edda Spiekerkoetter, MD
Edda Spiekerkoetter and Marlene Rabinovitch. Genomics in Pulmonary Arterial
Hypertension. Braunwald’s Heart Disease 9th edition, electronic version 2013.
Invited Speaker:
Pulmonary Grand Rounds, Lund University, Lund, Sweden, April 2013
Cardiovascular Institute Grand Rounds Karolinska Institute, Stockholm, Sweden, April
2013
American Thoracic Society (ATS) international conference, San Diego, May 2014:
Scientific Symposium: Novel Therapeutic strategies emerging from Genetic Studies in
Pulmonary Arterial Hypertension
Session Chair: Micheala Aldred and Edda Spiekerkoetter
Presenter: “FK506 increases BMP signaling and reverses pulmonary hypertension”
Pulmonary Hypertension Association conference (PHA) Indianapolis, June 2014:
- Invited Speaker in Scientific Session: New Treatments and Targets in PH:
“High throughput drug screening in PAH: From cells to people”
- Invited Panelist Medically Led Session “Familial/Genetics and PAH”– Chair: John
Newman
Oral presentations:
Wall Center Symposium, May 17, 2012
E. Spiekerkoetter: Vasoresponsiveness combined with capacitance is a prognostic
indicator in Pulmonary Arterial Hypertension
THOMAS L. PETTY ASPEN LUNG CONFERENCE
55th Annual Meeting, June 6-9, 2012
"Mechanics and Mechanisms of Pulmonary Hypertension”
Edda Spiekerkoetter: FK506 – identified in a high Throughput screen to increase BMPR2
signaling – reverses pulmonary hypertension by rescuing endothelial dysfunction.
Keystone Symposia on Pulmonary Vascular Disease and right Ventricular Dysfunction:
Current Concepts and future Therapies. Monterey Sep 10-15, 2012
Edda Spiekerkoetter: FK506 – identified in a high Throughput screen to increase BMPR2
signaling – reverses pulmonary hypertension by rescuing endothelial dysfunction
E Spiekerkoetter, Haghighat L, Haghighat R, Sawada H, Saito T, Wang L, de Jesus
Perez V, ten Dijke P, El-Bizri N, Solow-Cordero D, Beachy PA, Rabinovitch M. FK-506
(Tacrolimus), identified in a High Throughput Screen to Increase BMPRII Signaling,
Prevents Pulmonary Arterial Hypertension (PAH) in Mice with Endothelial BMPRII
Deletion. Mini-Symposium, ATS 2011 Denver.
E Spiekerkoetter, L Wang, R Zamanian, N Ambartsumian, AM Schmidt, E Lukanidin, M
Rabinovitch. Chloride intracellular channel 4 (CLIC4), a novel downstream target of Bone
Page 9
Edda Spiekerkoetter, MD
Morphogenetic Protein Receptor II (BMPR-II) in human pulmonary artery smooth muscle
cell (PASMC) migration. Oral presentation at the American Heart Association (AHA)
conference 2005, Dallas, TX.
E Spiekerkoetter, A Lawrie, SL Merklinger, M Rabinovitch. Mts1, a novel gene in the
pathogenesis of pulmonary hypertension, induces migration of human Pulmonary Artery
Smooth muscle cells via the Receptor for Advanced Glycation end products (RAGE). Oral
Presentation at the American Heart Association (AHA) Conference 2003, Orlando, FL.
E Spiekerkoetter, MM Hoeper, H Fabel. Acute hemodynamic effects of salbutamol
aerosol in patients with primary pulmonary hypertension. Oral presentation at the
American Thoracic Society (ATS) conference 2001, San Francisco, CA.
8. Research Support
Ongoing Research Support:
1K08HL107450-01
09/01/2011 - 07/31/2016
NIH
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
The goals of this project are to use new technologies to modulate BMP signaling using
High Throughput Screening of FDA approved drugs and bioactive compounds as well as
microRNA mimics and antagomirs.
Mentors: Marlene Rabinovitch, Phil Beachy
Role on Project: PI
2011 Pulmonary Hypertension Association (PHA) supplemental grant for awarded
K08 – in conjunction with 1K08HL107450-0- NIH
09/01/2011 - 08/31/2016
Modulating: BMPRII Signaling in Pulmonary Arterial Hypertension
Role on Project: PI
Spark Research Grant
03/1/2013 – 02/30/2014
Phase II trial of Tacrolimus in Pulmonary Hypertension
The goal of this project is to perform a phase II tolerability and efficacy study with
Tacrolimus in patients with pulmonary arterial hypertension with dysfunctional BMPRII
signaling.
Role on Project: Co-PI
Wall Center Seed Grant –
1/11/2011 – 31/10/2014
Vera Moulton Wall Center for Pulmonary Vascular Disease
Phase II trial of Tacrolimus in Pulmonary Hypertension
The goal of this project is to perform a phase II tolerability and efficacy study with
Tacrolimus in patients with pulmonary arterial hypertension with dysfunctional BMPRII
signaling.
Role on Project: Co-PI
Page 10
Edda Spiekerkoetter, MD
06/01/2012 - 05/30/2017
Wall Center Faculty Research Scholar: 1144545-101-GHDCK
Vera Moulton Wall Center for Pulmonary Vascular Disease
Developing novel therapies for pulmonary arterial hypertension by targeting the BMP
pathway
Role on Project: PI
CMREF – Pulmonary Hypertension Breakthrough Initiative (UL1RR024986)
01/2006- Present
Stanford IPAH Transplant and Preparation Center
Role on project: Co-Investigator
Completed Research Support:
09/2009 – 08/2011
K12 Career Development Program In Genetics and Genomics of Pulmonary
Diseases:
Director Prof. M Krasnow, Co-director Prof. M Rabinovitch
“Development of High-Throughput Screen of drugs that modulates bone morphogenetic
protein receptor II “
Role on Project: Trainee
2003 – 2005
Pulmonary Hypertension Association and AHA postdoctoral research fellowship
award
“Stromal Derived factor modulates homing and differentiation of stem cells in pulmonary
hypertension”
Role in Project: PI
NIH CTSA award UL1 RR025744
02/01/2012 – 01/31/2013
Spectrum Pilot Grant, Stanford University
PI: Harry Greenberg
Phase II trial of Tacrolimus in Pulmonary Hypertension
The goal of this project is to perform a phase II tolerability and efficacy study with
Tacrolimus in patients with pulmonary arterial hypertension with dysfunctional BMPRII
signaling. Our previous research has shown that low dose Tacrolimus can prevent and
reverse experimental pulmonary hypertension in mice and rats by restoring BMPR2
signaling and improving endothelial dysfunction.
Role on Project: Co-PI
Wall Center Seed grant: 1149670 -111-GHDGQ
09/01/2011- 12/31/2013
Vera Moulton Wall Center for Pulmonary Vascular Disease
Small Molecule Screen for compounds that activate BMPRII signaling
The goal of this project is to use High Throughput Screening to find new small molecules
that could potentially increase or inhibit BMP signaling.
Role on Project: PI
01/01/2013 – 012/31/2013
Cardiovascular Institute Seed Grant :
Page 11
Edda Spiekerkoetter, MD
Increasing BMP signaling to improve right ventricular function in congenital heart disease
Role on Project: PI
Collaborators: Dres Bernstein and Reddy, Pediatric Cardiology, Stanford
Page 12
Edda Spiekerkoetter, MD